Pediatric Intensive Care Unit, University Hospital of Padova, Padova, Italy.
Department of Woman's and Child's Health, University Hospital of Padova, Padova, Italy.
Perfusion. 2024 Sep;39(6):1113-1119. doi: 10.1177/02676591231176243. Epub 2023 May 12.
ExtraCorporeal Membrane Oxygenation (ECMO) in pediatric patients with COVID-19 has a survival rate similar to adults. Occasionally, patients may need to be cannulated by an ECMO team in a referring hospital and transported to an ECMO center. The ECMO transport of a COVID-19 patient has additional risks than normal pediatric ECMO transport for the possible COVID-19 transmissibility to the ECMO team and the reduction of the ECMO team performance due to the need of wearing full personal protective equipment. Since pediatric data on ECMO transport of COVID-19 patients are lacking, we explored the outcomes of the pediatric COVID-19 ECMO transports collected in the EuroECMO COVID_Neo/Ped Survey.
We reported five European consecutive ECMO transports of COVID-19 pediatric patients collected in the EuroECMO COVID_Neo/Ped Survey including 52 European neonatal and/or pediatric ECMO centers and endorsed by the EuroELSO from March 2020 till September 2021.
The ECMO transports were performed for two indications, pediatric ARDS and myocarditis associated to the multisystem inflammatory syndrome related to COVID-19. Cannulation strategies differed among patients according to the age of the patients, transport distance varied between 8 and 390 km with a total transport duration between 5 to 15 h. In all five cases, the ECMO transports were successfully performed without major adverse events. One patient reported a harlequin syndrome and another patient a cannula displacement both without major clinical consequences. Hospital survival was 60% with one patient reporting neurological sequelae. No ECMO team member developed COVID-19 symptoms after the transport.
Five transports of pediatric patients with COVID-19 supported with ECMO were reported in the EuroECMO COVID_Neo/Ped Survey. All transports were performed by an experienced multidisciplinary ECMO team and were feasible and safe for both the patient and the ECMO team. Further experiences are needed to better characterize these transports and draw insightful conclusions.
COVID-19 患儿接受体外膜肺氧合(ECMO)治疗的生存率与成人相似。偶尔,患者可能需要在转诊医院由 ECMO 团队进行插管,并转运至 ECMO 中心。与正常儿科 ECMO 转运相比,COVID-19 患者的 ECMO 转运存在额外风险,因为 COVID-19 可能会传播给 ECMO 团队,并且由于需要穿戴全套个人防护装备,可能会降低 ECMO 团队的工作效率。由于缺乏关于 COVID-19 患者 ECMO 转运的儿科数据,我们探索了在 EuroECMO COVID_Neo/Ped 调查中收集的 COVID-19 儿科 ECMO 转运的结果。
我们报告了在 EuroECMO COVID_Neo/Ped 调查中收集的五例 COVID-19 儿科患者的连续欧洲 ECMO 转运,包括 52 个欧洲新生儿和/或儿科 ECMO 中心,并得到了 EuroELSO 的认可,转运时间从 2020 年 3 月至 2021 年 9 月。
ECMO 转运的指征为儿科急性呼吸窘迫综合征和 COVID-19 相关多系统炎症综合征相关心肌炎。根据患者年龄,插管策略存在差异,转运距离在 8 至 390 公里之间,总转运时间在 5 至 15 小时之间。在所有五例患者中,ECMO 转运均成功完成,无重大不良事件发生。一例患者报告出现哈雷奎因综合征,另一例患者出现导管移位,但均无重大临床后果。患者的院内生存率为 60%,其中一例患者有神经后遗症。没有 ECMO 团队成员在转运后出现 COVID-19 症状。
在 EuroECMO COVID_Neo/Ped 调查中报告了五例 COVID-19 患儿接受 ECMO 支持的转运。所有转运均由经验丰富的多学科 ECMO 团队完成,对患者和 ECMO 团队均安全可行。需要进一步的经验来更好地描述这些转运,并得出有见地的结论。